Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 2/20 | 0.59 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.46 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.43 |
| ▸ | ATR | Q13535 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17622055 | 0.89 | SMARCA2 (0.56) | SMARCA2AAK1SMARCA4 | |
| SCHEMBL22432054 | 0.85 | SMARCA2 (0.43) | SMARCA2AAK1SMARCA4CYP17A1ATR | |
| SCHEMBL18862939 | 0.85 | CYP17A1 (0.42) | SMARCA2CYP17A1ATRCA12CA1 | |
| SCHEMBL5013603 | 0.85 | MAP4K4 (0.43) | SMARCA2CYP17A1ATRCA12CA1 | |
| SCHEMBL28639230 | 0.81 | CYP17A1 (0.41) | SMARCA2CYP17A1ATRCA12CA1 | |
| SCHEMBL1501665 | 0.80 | SMARCA2 (0.57) | SMARCA2SMARCA4CYP17A1ATRCA12 | |
| SCHEMBL30293080 | 0.80 | SMARCA2 (0.57) | SMARCA2AAK1SMARCA4CYP17A1ATR | |
| SCHEMBL16055308 | 0.80 | SMARCA2 (0.57) | SMARCA2AAK1SMARCA4CYP17A1ATR | |
| SCHEMBL21614653 | 0.79 | SMARCA2 (0.60) | SMARCA2SMARCA4CYP17A1ATRRXFP1 | |
| SCHEMBL29975585 | 0.79 | SMARCA2 (0.50) | SMARCA2SMARCA4CYP17A1ATRCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108473499-B | Novel pyrazolopyrimidine derivatives | 诺华股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-10442808-B2 | Pyrazolo pyrimidine derivatives and their use as MALT1 inhbitors | NOVARTIS AG (CH) | 2019-10-15 | — | — | US | disclosed |
| CN-106170489-B | New Pyrazolopyrimidine derivative and its purposes as MALT1 inhibitor | 诺华股份有限公司 | 2019-05-03 | — | — | CN | disclosed |
| CN-108473499-A | Novel Pyrazolopyrimidine derivative | 诺华股份有限公司 | 2018-08-31 | — | — | CN | disclosed |
| US-20180030061-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS | NOVARTIS AG (CH) | 2018-02-01 | — | — | US | disclosed |
| US-9815842-B2 | Pyrazolo pyrimidine derivatives and their use as MALT1 inhibitors | NOVARTIS AG (CH) | 2017-11-14 | — | — | US | disclosed |
| US-20170275270-A1 | BENZYL SUBSTITUTED INDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | US | disclosed |
| US-20170275270-A1 | BENZYL SUBSTITUTED INDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | US | disclosed |
| WO-2017081641-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2017-05-18 | — | — | WO | disclosed |
| US-20170121335-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS | NOVARTIS AG (CH) | 2017-05-04 | — | — | US | disclosed |
| CN-106170489-A | New Pyrazolopyrimidine derivative and the purposes as MALT1 inhibitor thereof | 诺华股份有限公司 | 2016-11-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030061-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS | MMEL1, MALT1, FBP1 | SMARCA2 2532/4885AAK1 385/4885SMARCA4 1991/4885 |
| US-20170275270-A1 | BENZYL SUBSTITUTED INDAZOLES | UGT2B7, CYP3A43, CYP3A7 | SMARCA2 2675/4885AAK1 4765/4885SMARCA4 2362/4885 |
| US-20170121335-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS | MMEL1, MALT1, FBP1 | SMARCA2 2532/4885AAK1 385/4885SMARCA4 1991/4885 |
| US-10442808-B2 | Pyrazolo pyrimidine derivatives and their use as MALT1 inhbitors | FBP1, MMEL1, MALT1 | SMARCA2 3478/4885AAK1 426/4885SMARCA4 2781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.